尊龙凯时 - 官网首页 -- 人生就是博!尊龙凯时人生就是博

Dorzagliatin as a Glucose Sensitizer Achieved Sustained Glycemic Control in Drug-Naïve T2D Patients in a 52-Week Phase 3 Monotherapy Trial (SEED Study)

2020 ADA Poster
Nov 02, 2022
3168

Online link unavailable, presentation available upon request. (BD@zgfhswm.com)

Focus Us
Copyright © 2024  Hua Medicine (Shanghai) Co., Ltd.    互联网药品信息服务资格证书编号: (沪)-非经营-2022-0079
沪ICP备83313474号-1  beiantubiao.png 沪公网安备 31011502013809号  Privacy Statement  Terms of Use
Search
How we use cookies
Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.
Accept
x
尊龙凯时人生就是博